Global

Congressional aides expect insider-trading ban on prediction markets to pass, while Canadians oppose

Published Jul 3, 2026Updated 64d ago

A slim majority of Capitol Hill aides expect legislation banning insider trading on platforms like Kalshi and Polymarket to pass, according to a Cryptobriefing survey of congressional staffers published July 6. A separate subscriber survey by The Logic found most respondents do not support legalizing prediction markets in Canada, with both Kalshi and Polymarket noted as having recently come under scrutiny. Sources did not specify timing or scope for the potential U.S. legislation.

Why this matters?

For Kalshi and Polymarket, congressional staff expectations of a ban create advance warning of a compliance burden they cannot yet scope or time. Both platforms must now budget for surveillance systems that flag congressional and staff trades without knowing whether the bill mandates disclosure, account closure, or criminal penalties.

The uncertainty is itself costly: legal teams and engineering cycles diverted to preemptive compliance are cycles not spent on product expansion or state preemption fights. Meanwhile, Canadian opposition closes a potential growth market where neither platform currently operates, removing a revenue hedge if U.S. sports contracts face federal restriction. The platforms face tightening margins on two borders at once.

In this story
Add Prediction News as a preferred source on GoogleGet our prediction-market coverage prioritized in your search results

Related Stories

More in Global
Legal

CFTC warns prediction markets to drop American-style moneyline odds

Legal

Appeals court rejects Kalshi bid to block Nevada gaming oversight

Legal

Kalshi issues first lifetime ban to George Santos over State of the Union bets

Legal

CFTC fines former White House teleprompter operator $172,000 for Kalshi insider trades

Global

UK regulator weighs easing ban on US-style prediction markets

Stocks

CME's Duffy clashes with CFTC chair and Kalshi at first event-contract advisory meeting